Clinical Trial

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Study acronym: NEOTIDE
Unknown Phase 2
View on ClinicalTrials.gov →
Summary
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Sintilimab plus chemotherapy in EGFR-mutant stage IIB-IIIB NSCLC (excluding N3) followed by optional adjuvant treatment upon investigators' decisions.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05244213
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Non-small Cell Lung Cancer, EGFR Activating Mutation
Enrollment 35 participants
Start Date 2022-06-04
Primary Completion 2024-06-05 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-08